NR 293 RUA Medication Teaching Plan

NR 293 RUA Medication Teaching Plan

Name

Chamberlain University

NR-293: Pharmacology for Nursing Practice

Prof. Name

Date

Medication Teaching Plan

Authors: Jaime Weisel and Nnamdi Omeludike
Course: Pharmacology for Nursing Practice
Instructor: Professor Gloria King-Hoff
Date: December 2018

This project focuses on Symproic, an oral opioid antagonist medication. Symproic is primarily prescribed to individuals suffering from Opioid Induced Constipation (OIC). As noted in the Journal for Managed Care and Formulary Management, “Opioid-induced constipation (OIC), new or worsening constipation occurring when initiating, changing, or increasing opioid use, represents the most common of these GI effects” (Hu & Bridgeman, 2018, p. 601). The target audience for our educational brochure includes adult patients diagnosed with chronic pain, which may stem from various conditions and who are receiving opioid analgesics for pain management. Research on Symproic’s safety and efficacy in children has not been conducted, thus our focus will remain on adult patients.

The brochure aims to creatively inform our audience about the complications associated with opioid use, as well as the adverse effects that can arise from these medications, highlighting the necessity of Symproic in their treatment regimen. In addition, it will detail how Symproic can alleviate some of the negative side effects associated with opioid use. Furthermore, we intend to educate patients about the therapeutic benefits of Symproic when prescribed appropriately. According to Markham (2017), “Symproic was associated with significantly greater improvements from baseline in the frequency of bowel movements per week compared with placebo (n = 620) at all assessed time points (weeks 12, 24, 36, and 52)” (p. 925).

Table: Overview of Symproic

References

Constipation too? Ready to make a move? (n.d.). Retrieved from https://www.symproic.com/

Hu, K., & Bridgeman, M. B. (2018). Naldemedine (Symproic) for the treatment of opioid-induced constipation. P&T: A Peer-Reviewed Journal for Managed Care & Formulary Management, 43(10), 601–627.

Kaufman, M. B. (2017). Pharmaceutical approval update. P&T: A Peer-Reviewed Journal for Managed Care & Formulary Management, 42(8), 502–504. Retrieved from https://chamberlainuniversity.idm.oclc.org/login?url=https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=124448428&site=eds-live&scope=site

Markham, A. (2017). Naldemedine: First global approval. Drugs, 77(8), 923–927. http://dx.doi.org.chamberlainuniversity.idm.oclc.org

NR 293 RUA Medication Teaching Plan

New drug approvals. (2017). P&T: A Peer-Reviewed Journal for Managed Care & Formulary Management, 42(5), 296–297. Retrieved from https://chamberlainuniversity.idm.oclc.org/login?url=https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=122620653&site=eds-live&scope=site

Symproic (Naldemedine Tablets): Side effects, interactions, warnings, dosage & uses. (n.d.). Retrieved from https://www.rxlist.com/symproic-drug.htm